Pharmaceutical composition comprising racemic aminopterin
There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.
1. A pharmaceutical composition comprising from 10% to 90% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 10% to 90% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition is adapted for oral administration.
3. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable salt of L-aminopterin or D-aminopterin is a disodium salt.
4. The pharmaceutical composition of claim 1 , wherein the amount of total aminopterin is from 0.01 mg to 4 mg.
5. The pharmaceutical composition of claim 1 , in the form of a tablet or capsule.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from 15% to 85% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 15% to 85% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition comprises from 25% to 75% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 25% to 75% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition comprises from 35% to 65% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 35% to 65% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition comprises from 45% to 55% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 45% to 55% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
10. A method for treating a disorder in a patient comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising from 10% to 90% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 10% to 90% (by weight) of D-aminopterin or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 wherein the therapeutically effective amount of total aminopterin is administered orally.
12. The method of claim 10 wherein the disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, arthritis, atopic dermatitis, inflammatory bowel disease, bronchopulmonary dysplasia, and canine atopic dermatitis.
13. The method of claim 10 further comprising using a second drug in a combination therapy.
14. The method of claim 13 wherein the second drug is folic acid.
15. The method of claim 10 wherein the therapeutically effective amount of aminopterin in the pharmaceutical composition is less than 0.3 mg total aminopterin per kilogram of patient body weight.
16. A method for treating disorders modulated by at least dihydrofolate reductase activity, said method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising from 10% to 90% (by weight) of L-aminopterin or a pharmaceutically acceptable salt thereof and from 10% to 90% (by weight) of D-aminopterin, or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , wherein the therapeutically effective amount of the pharmaceutical composition is administered orally.
18. The method of claim 16 , wherein the disorder is selected from the group consisting of leukemia, lymphoma, breast cancer, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, arthritis, atopic dermatitis, inflammatory bowel disease, bronchopulmonary dysplasia, and canine atopic dermatitis.